



HEDLEY TECHNOLOGIES INC.

FOR IMMEDIATE RELEASE

HEDLEY TO CHANGE NAME TO BIOSYENT INC.

MISSISSAUGA, ONTARIO (June 5, 2006) The Board of Directors announces that Hedley Technologies Inc. ("Hedley", TSX Venture: HED) will change its name to BioSyent Inc. ("BioSyent") effective June 13, 2006. On that date, the company's trading symbol on the TSX Venture Exchange will change to RX. The change in name reflects the company's forward focus on human health, specifically the pharmaceutical market.

The name change to BioSyent and the change in trading symbol to RX do not affect shareholder's ownership positions in the company and shareholders are not required to take any action with respect to the changes.

Hedley continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.

Hedley Technologies Inc. is a publicly traded life science company that acquires or licences products and commercializes proprietary science-based technologies that advance human health and public safety. Hedley's common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol HED.

For additional information contact:

René C. Goehrum, Chairman and CEO

rgoehrum@hedleytech.com

Tel: (905) 206-0013

www.hedleytech.com

Fax: (905) 206-1413

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of same.